TY - JOUR T1 - Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States JF - medRxiv DO - 10.1101/2021.05.10.21256996 SP - 2021.05.10.21256996 AU - Pratha Sah AU - Thomas N. Vilches AU - Affan Shoukat AU - Meagan C. Fitzpatrick AU - Abhishek Pandey AU - Burton H. Singer AU - Seyed M. Moghadas AU - Alison P. Galvani Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/18/2021.05.10.21256996.abstract N2 - Recent evidence suggests that some new SARS-CoV-2 variants with spike mutations, such as P.1 (Gamma) and B.1.617.2 (Delta), exhibit partial immune evasion to antibodies generated by natural infection or vaccination. By considering the Gamma and Delta variants in a multi-variant transmission dynamic model, we evaluated the dominance of these variants in the United States (US) despite mounting vaccination coverage and other circulating variants. Our results suggest that while the dominance of the Gamma variant is improbable, the Delta variant would become the most prevalent variant in the US, driving a surge in infections and hospitalizations. Our study highlights the urgency for accelerated vaccination and continued adherence to non-pharmaceutical measures until viral circulation is driven low.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAPG acknowledges funding from NSF Expeditions grant 1918784, NIH grant 1R01AI151176-01, NSF grant RAPID-2027755 and the Notsew Orm Sands Foundation. SMM was supported by the Canadian Institutes of Health Research [OV4 - 170643, COVID-19 Rapid Research] and Natural Sciences and Engineering Research Council of Canada, NSERC EIDM grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required as all data is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials. The simulation codes are available at: https://github.com/thomasvilches/multiple_strains https://github.com/thomasvilches/multiple_strains ER -